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Abstract. Continuous research activities in the field of nanomedicine in the past decade have, to a great extent, been 
focused on nanoparticle technologies for cancer therapy. Gold and iron oxide nanoparticles (NP) are two of the most 
studied inorganic nanomaterials due to their unique optical and magnetic properties. Both types of NPs are emerging as 
promising systems for anti-tumor drug delivery and for nanoparticle-mediated thermal therapy of cancer. In thermal 
therapy, localized heating inside tumors or in proximity of tumor cells can be induced, for example, with Au NPs by 
radiofrequency ablation heating or conversion of photon energy (photothermal therapy) and in iron oxide magnetic NPs 
by heat generation through relaxation in an alternating magnetic field (magnetic hyperthermia). Furthermore, the 
superparamagnetic properties of iron oxide nanoparticles have led to their use as potent MRI (magnetic resonance 
imaging) contrast agents. Surface modification/coating can produce NPs with tailored and desired properties, such as 
enhanced blood circulation time, stability, biocompatibility and water solubility. To target nanoparticles to specific tumor 
cells, NPs should be conjugated with targeting moieties on the surface which bind to receptors or other molecular 
structures on the cell surface. The article presents several approaches to enhancing the specificity of Au and iron oxide 
nanoparticles for tumor tissue by appropriate surface modification/functionalization, as well as the effect of these 
treatments on the saturation magnetization value of iron oxide NPs. The use of other nanoparticles and nanostructures in 
cancer treatment is also briefly reviewed. 
INTRODUCTION 
The multidisciplinary field of Nanotechnology involving physics, chemistry, biology and engineering, has 
opened new horizons in diagnostics and therapeutics, and especially in the diagnosis and treatment of cancer [1–6]. 
After cardiovascular diseases, cancer is the second leading cause of death worldwide. Despite rapid developments of 
diagnostic techniques, surgery techniques, pharmaceutical chemistry and chemotherapy, detection and therapy of 
cancer at the initial stage remains a major challenge. In the last decade, great attention has been focused on 
development of nanoparticles and nanoparticle-targeting molecules systems for drug delivery [1–14], hyperthermia 
tumor treatment [15–19] and MRI—magnetic resonance imaging diagnostics [20–24]. New approaches were 
successfully introduces in cancer therapy. 
Compared to micron-scale particles, nanoparticles are better suited for intravenous administration. They are 
much smaller than the smallest capillaries (5 μm) and thus can pass through capillary systems of organs and tissues 
without the risk of vessel embolism. Nanoparticles (diameter <100 nm) are generally less recognized by the immune 
system and can circulate for several hours in the blood stream. Due to their small size, nanoparticles are able to 
diffuse through fenestrations of the altered blood vessels found in diseased tissues (Fig. 1), cross biological 
membranes and access cells, tissues and organs that micron-sized particles normally cannot. Small nanoparticles 
(10–100 nm) that avoid recognition (‘stealth nanoparticles’) can accumulate in neoplastic tissues—‘enhanced 
permeability and retention’ (EPR) effect. Particles ?100 nm are rapidly removed from circulation by mononuclear 
phagocytic cells, located primarily in the liver and spleen. Such particles accumulate in liver and spleen before they 
are able to reach the site of disease (hepatic filtration) [25]. Particles <5.5 nm are cleared by excretion (renal 
filtration–kidneys) [26]. 
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FIGURE 1. A schematic of enhanced permeability and retention effect (EPR)— 
passive extravasation of nanoparticles through leaky tumor vasculature 
Currently there are three major applications of nanoparticles in cancer therapy: 
(1) drug delivery;  
(2) magnetic and radio-frequency (RF) hyperthermia of cancer; 
(3) magnetic resonance imaging (MRI). 
Gold and iron oxide nanoparticles (NP) are the two most studied inorganic nanomaterials. Both are biocom-
patible, relatively non-toxic, possess unique physical properties and are emerging as promising systems for anti-
tumor drug delivery and for nanoparticle-mediated thermal therapy of cancer. Iron oxide NPs are also used in 
magnetic resonance imaging (MRI) of tumors. It can be mentioned that as a result of metabolic degradation of iron 
oxide NPs iron ions are added to the body’s iron stores and eventually incorporated by erythrocytes as hemoglobin 
allowing for their safe use in vivo.
In addition to gold and iron oxide NPs, mesoporous silica [14, 27], carbon nanotubes [28, 29], CdS, CdSe 
nanoparticles [30] as well as natural therapeutics such as Nisin [31] and Curcumin [32, 33] are also studied in 
antitumor treatments. Hollow nanoparticles are used for encapsulation of antitumor drugs [14, 34]. To target 
nanoparticles to specific tumor cells, NPs are conjugated with targeting moieties on the surface that bind to receptors 
or other molecular structures on the cell’s surface [1–12]. In many cases, combination of NPs drug delivery with 
magnetic resonance imaging (MRI), MRI with magnetic hyperthermia as well as photothermal and radiofrequency 
ablation therapy with chemotherapy are employed in cancer therapy. 
TARGETED NANOPARTICLES—DRUG DELIVERY TO TUMORS 
For their effective use in medical applications in general and in cancer therapy and diagnostics in particular, 
nanoparticles should be preferably bio-functionalized. In the last decade, surface functionalization of nanoparticles 
with biomolecules for targeted drug delivery to tumors has been a top priority in biomedical technology. Targeted 
delivery of nanoparticles to a specific tissue can be achieved by conjugation with particular biological ligands that 
will direct the particle in the bloodstream to the tumor (see schematic in Fig. 2). Also shown in the figure is the 
transformation of the targeted NP into a drug-delivery vehicle by attaching an anti-cancer drug to the particle surface. 
FIGURE 2. A schematic of NP surface bio-functionalization 
for active tumor targeting 
FIGURE 3. A schematic of iron oxide NP bio-
functionalization for targeting toward diseased  
cells: attachment of a Phosphonate-Anchored  
SAM having an antibody binding tail [37] 
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FIGURE 4. Schematics of (a) magnetic iron oxide NP’s clusters, (b) ferri-liposome and (c) ferri-liposome size distribution [40] 
Nanoparticles allow for in vivo delivery of challenging drugs (nucleic acids, peptides, proteins, molecules 
difficult to solubilize). The therapeutic indices of drugs can be increased after association with nanoparticles, and the 
bio-availability and stability of drugs can be improved in nanoparticles. Targeted nanoparticles can deliver drugs 
directly to diseased organs and into drug-resistant cells. In a targeted NP, the drug is encapsulated inside the core to 
protect the drug from being degraded in the body before it reaches its target and to prevent the drug from interacting 
with normal cells, thus avoiding side effects. The surface characteristics of a NP shell should allow the attachment 
of molecules that bind particular cellular receptors for the nanoparticle to actively target cells expressing the 
receptor.
Iron oxide nanoparticles (IONPs) consisting of maghemite (?-Fe2O3) and/or magnetite (Fe3O4) have been 
extensively studied due to their low toxicity and a unique magnetic property—superparamagnetism. Single domain 
IONPs become superparamagnetic below a critical size of 30–50 nm: they may have high saturation magnetization 
and, as a result, high magnetic energy when an external magnetic field is applied, and at the same time practically 
zero residual magnetization. Successful in vivo usage of IONPs requires particles below 100 nm in size that are well 
dispersed in physiological media.  
Since bare IONPs are not stable in water or in physiological fluids, they tend to agglomerate and precipitate 
quickly [35]. To promote dispersion in aqueous media, iron oxide cores are often coated with polymers, for 
example, dextran [36]. These organic layers can also provide NP’s with functional terminal groups that can be used 
for attaching targeting agents. One drawback of the surface engineered IONPs is that the polymer coatings cause a 
significant increase in the overall hydrodynamic diameter of nanoparticles, resulting in decreased magnetic contrast. 
In [37] it was shown that application of phosphonate-anchored ultrathin self-assembled monolayers (SAMs) as 
coatings for such particles results in increase of superparamagnetic core diameter with overall diameter being within 
the required nanoscale range (Fig. 3). This should lead to a substantial increase of magnetic energy and increase of 
magnetic contrast. Magnetic nanoparticles encapsulated within a phospholipid bilayer, forming liposomes, have 
been reported to have considerable structural and pharmacokinetic advantages for drug delivery [38, 39]. Owing to 
their ability to encapsulate both hydrophobic and hydrophilic therapeutics, liposomes prevent local dilution of the 
drug and limit its interaction with the surrounding environment, enabling reduction of the therapeutic dose and toxicity.
An example of using iron oxide NP clusters encapsulated inside liposomes was reported in [40] (Fig. 4). Under the 
influence of an external magnet, such ferri-liposomes target both the tumor and its microenvironment, substantially 
reducing the size of the tumor in a mouse after treatment. 
Multi-functional gold (Au) NPs are highly stable and versatile scaffolds for drug delivery due to their unique size, 
chemical and physical properties. Surface bio-functionalization of Au nanoparticles provides the possibility of 
targeting specific cells and thus destructing cancer cells (Fig. 2). Gold NPs have advantages in binding targeting 
ligands. A number of different types of ligands including branched molecules, dendrimers, can be attached to Au 
nanoparticles, in order to target different tumor cells. The release of drugs from gold NPs can be controlled by 
external light in the wave length range where tissues are transparent (near-infrared, NIR), or by intracellular 
glutathione mediate release [41–43] (Fig. 5) (glutathione is an important antioxidant preventing damage to some 
important cellular components). The presence of certain hormone receptors on cancer cells can be utilized for active 
targeting of nanoparticles. In [44], for example, the delivery efficiency of an anti-tumor drug was significantly 
improved through decorating Au NPs with specific ligands that can recognize and selectively bind to estrogen 
receptors overexpressed in breast cancer cells and to androgen receptors over expressed in prostate cancer cells.  
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FIGURE 5. Schematic mechanisms of drug release from Au 
NPs [41] 
FIGURE 6. A schematic of rattled mesoporous silica NP  
in gold nanoshell for targeted drug release 
Mesoporous silica NPs and rattled mesoporous silica NPs in gold nanoshells (see schematic in Fig. 6) are also used 
in drug delivery and chemotherapy of cancer [14, 27, 44]. 
NANOPARTICLES—HYPERTHERMIA TREATMENT OF CANCER 
Magnetic Hyperthermia 
Superparamagnetic NPs, such as iron oxide NPs, or magnetic nanoparticles, such as, for example, cobalt ferrite 
CoFe2O4, NPs [45], can generate heat through relaxation in an alternating magnetic field. The heating effects are 
related to losses during the magnetization reversal process and/or to hysteresis losses. Magnetic hyperthermia is a 
promising treatment of tumors. As discussed above (see Figs. 2 and 3), targeting ligands can direct iron oxide or 
magnetic NPs to the tumor. Upon application of an external AC magnetic field, the heat generated by magnetic 
nanoparticles is transferred into the neighboring diseased tissue, and, if the temperature is locally maintained above 
42°C for more than half an hour, the tumor cells are destroyed or, at least, their growth is reduced [46]. The heat 
generated in the vicinity of superparamagnetic iron oxide or magnetic nanoparticles by induced eddy current is very 
small and should not damage normal cells [47]. To burn away the cancer cells, the frequency of alternating magnetic 
field and exposure should be adjusted for each type of nanoparticle. A schematic of application of magnetic 
nanoparticles for Hyperthermia therapy and MRI diagnosis of tumors is shown in Fig. 7.  
Radio-Frequency (RF) Heating Hyperthermia—RF Ablation 
Selective heating of conducting but non-magnetic nanoparticles can be achieved by application of a radio-
frequency alternating electric field resulting in eddy currents. The phenomenon is known as induction heating or 
high frequency induction heating and is used in processing metal alloy parts as well as parts made of other 
conducting materials such as carbon and carbon-fiber composites.  
FIGURE 7. A schematic of magnetic nanoparticles application 
for Hyperthermia therapy and MRI diagnosis of tumors 
FIGURE 8. In vitro liver cancer HepG2 cells exposed  
to 35 W in the RF field in the presence or absence  
of Au NPs in water solution as a function of time [48] 
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The eddy current and the generated heat depend on electric resistance. Since the resistance of nanoparticles is 
high, the currents are very small. This may be advantageous when only small overheating is needed to destroy 
cancer cells without damaging normal cells. Damage and destruction of cancer or other disfunctional tissues by 
applying a radio-frequency electromagnetic field is called RF ablation. Radiofrequency heating of gold NPs is 
widely used in research and clinical practice for cancer therapy [4, 12, 13, 48, 49]. For example, 80% of HepG2 
liver cancer cells cultured in solutions containing gold NPs heated by 35W RF died upon a 7 min exposure vs. only 
15% of cells in the control water solution [48] (see Fig. 8). Due to the unique property of localized surface plasmon 
resonance, gold nanoparticles (including gold nanoshells and nanorods) produce heat when excited by visible-NIR 
light. This photothermal energy conversion makes Au NPs excellent probes for hyperthermia application in cancer 
treatment [49]. Carbon nanotubes absorb infrared radiation (IR) in the range between 700 and 1100 nm, where body 
tissues are most transparent. Absorbed IR promotes molecular oscillation leading to local heating of the surrounding 
tissue—hyperthermia, and destruction of cancer cells [50]. 
IRON OXIDE NANOPARTICLES—MRI CONTRAST AGENTS 
Magnetic resonance imaging (MRI) is a non-invasive diagnostic medical imaging technique (schematic in Fig. 7) 
that uses the interaction between strong magnetic field RF pulses and hydrogen nuclei in the body tissues. When a 
strong magnetic field is applied, hydrogen nuclei align with the direction of this field and create a net magnetic 
moment. Once the RF signal is removed, the hydrogen nuclei realign themselves with the magnetic field in the 
process called relaxation. When the hydrogen nuclei relax and lose their energy, they emit a radio wave signal which 
can be detected by an external coil and then converted to an image in the MRI system. MRI imaging sensitivity can 
be greatly improved via administration of contrast agents. Over the last decade, much attention has been devoted to 
the development of superparamagnetic iron oxide (SPIO) NPs as contrast agents for MRI [6, 9, 10, 16, 24, 51]. 
Experiments are also going on with superparamagnetic Gd as a contrast agent [24]. In [52] Gd was deposited on 
single wall carbon nanotubes for MRI and hyperthermia therapy. 
CONCLUSION 
NPs are well suited for intravenous administration; they are able to diffuse through fenestrations of the altered 
blood vessels found in diseased tissues, cross biological membranes and access cells, tissues and organs that micron-
sized particles normally cannot. 
Iron oxide and gold nanoparticles (NPs) are emerging as promising systems for anti-tumor drug delivery and for 
nanoparticle-mediated thermal therapy and diagnostics of cancer: 
– targeted drug delivery; 
– hypothermia–destruction of cancer cells by overheating; 
– MRI—magnetic resonance imaging. 
Active targeting of NPs by conjugation with specific ligands which have high affinity to receptors over 
expressed on cancer cells may facilitate their delivery to cancerous tumors and cells; drugs can be encapsulated in 
meso- or nanopores of NPs or attached to the NPs’ surfaces. 
Other NPs, such as mesoporous silica, carbon nanotubes, CdS/CdSe, polymers, as well as natural therapeutics, 
such as Nisin and Curcumin, are also studied as anticancer agents. 
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